NCT04263181

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.

Conditions

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Interventions

Type	Name	Description
PROCEDURE	Peripheral blood draw	* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy * Cohort 0 or 1 - peripheral blood draw on Day 2 * Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3 * Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery) * Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28
PROCEDURE	Bone marrow aspirate	* Cohort 0 or 1 - bone marrow aspirate on Day 14 * Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery) * Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28
PROCEDURE	Buccal swab	* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery) * Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28

Timeline

• Start date: 2020-01-29
• Primary completion: 2027-01-31
• Completion: 2027-01-31
• First posted: 2020-02-10
• Last updated: 2026-03-02

Locations

1 site across 1 country: United States